Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Sialic Acid in Patients With Glucosamine (UDP-N-acetyl)-2-epimerase Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM) (GNEM)

• ClinicalTrials.gov Identifier: NCT02377921
• Recruitment Status: Completed
• First Posted: March 4, 2015
• Results First Posted: July 9, 2018
• Last Update Posted: June 27, 2019
• Sponsor: Ultragenyx Pharmaceutical Inc
• Information provided by (Responsible Party): Ultragenyx Pharmaceutical Inc

Study Description

Brief Summary:

The primary objective of this study is to evaluate the effect of 6 g/day aceneuramic acid extended-release (Ace-ER) treatment of participants with GNEM on upper extremity muscle strength (upper extremity composite [UEC] score) as measured by dynamometry.

Condition or disease	Intervention/treatment	Phase
Hereditary Inclusion Body Myopathy; Distal Myopathy With Rimmed Vacuoles; Distal Myopathy, Nonaka Type; GNE Myopathy	Drug: aceneuramic acid extended-release (Ace-ER); Drug: Placebo	Phase 3

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 89 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Sialic Acid Extended-Release Tablets in Patients With GNE Myopathy (GNEM) or Hereditary Inclusion Body Myopathy (HIBM)
• Actual Study Start Date: May 20, 2015
• Actual Primary Completion Date: June 9, 2017
• Actual Study Completion Date: June 9, 2017

Arms and Interventions

Arm	Intervention/treatment
Experimental: Aceneuramic Acid Extended-Release (Ace-ER); Ace-ER 6 g/day, divided 3 times per day (TID) for 48 weeks.	Drug: aceneuramic acid extended-release (Ace-ER); tablets for oral use; Other Names: UX001; sialic acid extended-release (SA-ER)
Placebo Comparator: Placebo; Matching placebo TID for 48 weeks.	Drug: Placebo; tablets for oral use

Outcome Measures

Primary Outcome Measures :

1. Change From Baseline in UEC Score (Total Force in kg) at Week 48 [ Time Frame: Baseline, Week 48 ]
   Muscle strength based on the maximum voluntary isometric contraction (MVIC) against a dynamometer was measured bilaterally in the following upper extremity muscle groups: gross grip, shoulder abductors, elbow flexors, and elbow extensors. The UEC is derived from the sum of the average of the right and left total force values (measured in kg).

Secondary Outcome Measures :

1. Change From Baseline in Muscle Strength in the Knee Extensors at Week 48 [ Time Frame: Baseline, Week 48 ]
   Lower extremity muscle strength in the knee extensors was measured by dynamometry. Bilateral total force was defined as the average of the right and left force values (measured in kg).
2. Change From Baseline in LEC Score (Total Force in kg) at Week 48 [ Time Frame: Baseline, Week 48 ]
   Muscle strength based on MVIC against a dynamometer was measured bilaterally in the following lower extremity muscle groups: knee flexors, hip flexors, hip extensors, hip abductors and hip adductors. The LEC is derived from the sum of the average of the right and left total force values (measured in kg).
3. Change From Baseline in GNEM FAS Mobility Domain Score at Week 48 [ Time Frame: Baseline, Week 48 ]
   Lower extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the lower extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.
4. Change From Baseline in Number of Lifts in the 30 Second Weighted Arm Lift Test at Week 48 [ Time Frame: Baseline, Week 48 ]
   Upper extremity function was assessed using a weighted arm lift test performed bilaterally. The number of times the participant can raise a 1 kg weight above the head in a 30-second period was recorded.
5. Change From Baseline in Number of Stands in the Sit to Stand Test at Week 48 [ Time Frame: Baseline, Week 48 ]
   Lower extremity function was assessed using a sit-to-stand test. The number of times the participant can rise from a seated to a standing position in a 30-second period was recorded.
6. Change From Baseline in Meters Walked in the 6MWT at Week 48 [ Time Frame: Baseline, Week 48 ]
   The total distance walked (meters) in a 6-minute period was measured.
7. Change From Baseline in Percent Predicted Meters Walked in the 6MWT at Week 48 [ Time Frame: Baseline, Week 48 ]
   The total distance walked (meters) in a 6-minute period was measured, and the percent predicted distance based on normative data for age and gender was estimated.
8. Change From Baseline in GNEM FAS Upper Extremity Domain Score at Week 48 [ Time Frame: Baseline, Week 48 ]
   Upper extremity use and function was assessed using the Mobility domain of the GNEM-FAS instrument a disease-specific measure developed to assess the functional impact of changes in muscle strength on mobility (reflective of the upper extremities). This mobility score ranges from 0 to 40 with higher scores representing greater mobility.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 55 Years (Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female, aged 18 to 55 years, inclusive
• Willing and able to provide written, signed informed consent after the nature of the study has been explained, and before any research-related procedures are conducted
• Have a documented diagnosis of GNEM, HIBM, distal myopathy with rimmed vacuoles (DMRV), or Nonaka disease due to previously demonstrated mutations in the gene encoding the GNE/N-acetylmannosamine kinase (MNK) enzyme (genotyping will not be conducted in this study)
• Able to provide reproducible force in elbow flexors (i.e. two dynamometry force values with no more than 15% variability in the dominant arm) at Screening
• Able to walk a minimum of 200 meters during the six-meter walk test (6MWT) at Screening without the use of assistive devices, including a cane, crutch(es), walker, wheelchair or scooter (ankle foot orthosis/orthoses are permitted)
• Willing and able to comply with all study procedures
• Participants of child-bearing potential or with partners of child-bearing potential who have not undergone a bilateral salpingo-oophorectomy and are sexually active must consent to use a highly effective method of contraception as determined by the site investigator (i.e. oral hormonal contraceptives, patch hormonal contraceptives, vaginal ring, intrauterine device, physical double-barrier methods, surgical hysterectomy, vasectomy, tubal ligation, or true abstinence [when this is in line with the preferred and usual lifestyle of the subject], which means not having sex because the subject chooses not to), from the period following the signing of the informed consent through 3 months after last dose of study drug
• Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause for at least two years, have had tubal ligation at least one year prior to Screening, or who have had a total hysterectomy or bilateral salpingo-oophorectomy

Exclusion Criteria:

• Ingestion of N-acetyl-D-mannosamine (ManNAc), sialic acid (SA), or related metabolites; intravenous immunoglobulin (IVIG); or anything that can be metabolized to produce SA in the body within 60 days prior to the Screening Visit
• History of more than 30 days treatment with SA-ER and/or Sialic Acid Immediate Release (SA-IR) in prior clinical trials in the past year
• Has had any hypersensitivity to SA or its excipients that, in the judgment of the investigator, places the subject at increased risk for adverse effects
• Has serum transaminase (i.e. aspartate aminotransferase [AST] or gamma-glutamyl transpeptidase [GGT]) levels greater than 3X the upper limit of normal (ULN) for age/gender, or serum creatinine of greater than 2X ULN at Screening
• Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) at any time during the study
• Use of any investigational product or investigational medical device within 30 days prior to Screening, or anticipated requirement for any investigational agent prior to completion of all scheduled study assessments
• Has a condition of such severity and acuity, in the opinion of the investigator, that it warrants immediate surgical intervention or other treatment or may not allow safe participation in the study
• Has a concurrent disease, active suicidal ideation, or other condition that, in the view of the investigator, places the subject at high risk of poor treatment compliance or of not completing the study, or would interfere with study participation or would affect safety

Contacts and Locations

Locations

United States, California

University of California, Irvine

Irvine, California, United States, 92697

United States, Missouri

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110

United States, New York

New York University School of Medicine

New York, New York, United States, 10016

Icahn School of Medicine at Mount Sinai

New York, New York, United States, 10029

Bulgaria

UMHAT "Alexandrovska"

Sofia, Bulgaria

Canada, Ontario

McMaster University

Hamilton, Ontario, Canada, L8N3Z5

France

CHU La Réunion - site GHSR

Saint-Pierre, Reunion, France

Institut de Myologie GH Pitié-Salpêtrière

Paris, France

Israel

Hadassah-Hebrew University Medical Center

Jerusalem, Israel

Italy

University of Messina

Messina, Italy

University of Milan

Milan, Italy

Università Cattolica

Rome, Italy

United Kingdom

The Newcastle upon Tyne Hospitals

Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NE1 4LP

Sponsors and Collaborators

Ultragenyx Pharmaceutical Inc

  Study Documents (Full-Text)

Documents provided by Ultragenyx Pharmaceutical Inc:

Study Protocol  [PDF] May 25, 2017

Statistical Analysis Plan  [PDF] May 26, 2017

More Information

Publications of Results:

Lochmuller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, Tarnopolsky M, Pogoryelova O, Woods C, Lai A, Shah J, Koutsoukos T, Skrinar A, Mansbach H, Kakkis E, Mozaffar T. A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy. Neurology. 2019 Apr 30;92(18):e2109-e2117. doi: 10.1212/WNL.0000000000006932. Epub 2019 Jan 25.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Tandon PK, Kakkis ED. The multi-domain responder index: a novel analysis tool to capture a broader assessment of clinical benefit in heterogeneous complex rare diseases. Orphanet J Rare Dis. 2021 Apr 19;16(1):183. doi: 10.1186/s13023-021-01805-5.

• Responsible Party: Ultragenyx Pharmaceutical Inc
• ClinicalTrials.gov Identifier: NCT02377921
• Other Study ID Numbers: UX001-CL301
• First Posted: March 4, 2015
• Results First Posted: July 9, 2018
• Last Update Posted: June 27, 2019
• Last Verified: June 2019

Keywords provided by Ultragenyx Pharmaceutical Inc:

GNE Myopathy; GNEM; HIBM; Nonaka; Hereditary Inclusion Body Myopathy; DMRV

Additional relevant MeSH terms:

Muscular Diseases; Distal Myopathies; Musculoskeletal Diseases; Neuromuscular Diseases; Nervous System Diseases; Muscular Dystrophies; Muscular Disorders, Atrophic; Genetic Diseases, Inborn